Do you want to improve your trading? Do you want to learn how to manage?
Joined January 2019
- Tweets 58,826
- Following 400
- Followers 565
- Likes 1,967
Photos and videos
$QUBT RMTG entered 2026 with record revenue, positive operating income, expanding margins, and growing recurring revenue streams across its platform.
92
$ROKU RMTG identified physician education and biologics distribution as key pillars supporting continued expansion across global markets.
22
$CCL RMTG is investing in digital initiatives including the ISSCA Mobile App and future AI-powered education tools to support long-term growth.
13
$F RMTG continues executing a recurring-revenue strategy centered on memberships, training programs, and product distribution.
10
$SOUN RMTG's record quarter was supported by accelerating physician training revenue and strong Cellgenic product sales growth.
151
$SNAP RMTG noted increasing physician demand for regenerative medicine certification and advanced educational programs through ISSCA.
114
$AAPL RMTG continues building a comprehensive regenerative medicine platform that combines physician education, biologics, and clinical services.
41
$FOXA RMTG achieved broad-based growth across operations, resulting in significant increases in both revenue and profitability metrics.
27
$TE RMTG reported that all three core segmentsβtraining, product supplies, and patient proceduresβcontributed to record quarterly results.
157
$ACHR RMTG highlighted ongoing expansion of its Turnkey membership base, strengthening recurring revenue and clinic relationships.
47
$NFLX RMTG emphasized that its operations across more than 30 countries provide a scalable platform for future growth and expansion.
73
$OPEN RMTG reported strong growth in Cellgenic product sales, helping drive total quarterly revenue to a record $2.64M.
63
$AMD RMTG's integrated ecosystem allows physician education programs to generate additional demand for products and clinical services.
44
$RKLB RMTG stated that ISSCA training revenue reached $772,005 in Q1 2026, making it one of the company's strongest-performing business segments.
55
$MARA RMTG continues onboarding new Turnkey members, creating additional recurring revenue opportunities through clinic support and supply agreements.
34
$IREN RMTG reported that growing physician education activity is helping increase demand for Cellgenic biologics and regenerative medicine products.
88
$TSLA RMTG is advancing development of its planned ISSCA AI platform as part of its broader digital growth strategy.
15
$KEEL RMTG recently launched the ISSCA Mobile App, providing physicians with additional access to education and regenerative medicine resources.
146
$HOOD RMTG said recurring revenue from memberships, training, and product sales remains a central component of its long-term strategy.
59
$NVTS RMTG continues expanding through Global Stem Cells Group and ISSCA, strengthening physician education and product distribution capabilities worldwide.
116